Continuous intake study of test beverage - A randomized, double-blind, placebo-controlled study -

Continuous intake study of test beverage - A randomized, double-blind, placebo-controlled study - - A randomized, double-blind, placebo-controlled, continuous intake study of test beverage

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000054729

Enrollment

Registered

2025-06-23

Start date

2024-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

intake of test beverage, two 500mL bottles per day, for 4 weeks intake of placebo beverage, two 500mL bottles per day, for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age: 20 to less than 70 years 2. Japanese males and females 3. Capable of data entry on electronic diary via a smartphone or PC 4. Individuals who have received adequate explanation regarding the trial, can comprehend its contents, and have produced written consent

Exclusion criteria

Exclusion criteria: 1.Currently undergoing medical, pharmacological, or herbal treatment (except for on-demand medicines) 2.Currently have serious hepatic, renal, cardiac, respiratory, endocrine, or metabolic disease 3.Have a risk of allergies to the test beverage 4.Regularly taking commercially available pharmaceuticals, quasi drugs, food for specified health use (FOSHU), health food, or supplements, and unable to stop taking during the test period 5.Have a history of or current food / drug allergy 6.Habitual heavy drinkers (benchmark: daily pure alcohol consumption exceeding 40g) 7.Heavy smokers (benchmark: 21 cigarettes per day or more) 8.Those planning major lifestyle changes (diet, sleep, exercise habits, etc.) during the test period 9.Those planning travel abroad during the test period 10.Currently pregnant or breastfeeding, or hoping to get pregnant during the test period 11.Participants in other clinical trials, within one month before consent to participate in this study, or planning to participate in other clinical trials during the test period of this study 12.Individuals deemed unsuitable for the trial by the principal investigator or co-principal investigator

Design outcomes

Primary

Measure	Time frame
incidence rate of side effects	—

Secondary

Measure	Time frame
Body weight, BMI, blood pressure, pulse, hematological examination, biochemical blood test, urinalysis, incidence rate of adverse events	—

Countries

Japan

Contacts

Public ContactHirokuni Kayama

IMEQRD Co., Ltd. Planning and Sales Department

clinical-trial@imeqrd.co.jp03-6704-5968

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026